The Recurrent Fracture Trial enrolled patients post hip fracture (mean age 74 ± 9.5 years; 55% > 75 years) and the main outcomes reported in this mixed age cohort were a reduction in new clinical fracture (35%; p = 0.001), new clinical vertebral fracture (p = 0.002), non-vertebral fracture (p = 0.03) but not hip fracture (p = 0.5). They also reported an overall mortality benefit (RR 0.7; 95%CI 0.6–0.9; p = 0.01).